Huachansu combined with chemotherapy for advanced gastrointestinal malignancies: a systematic review and meta-analysis with formulation-stratified analyses
Abstract
AimTo evaluate the clinical effects of Huachansu combined plus chemotherapy compared with chemotherapy alone in advanced gastrointestinal malignancies and to explore potential variation in treatment-effect estimates across Huachansu formulations.MethodsPubMed, Web of Science, the Cochrane Library, China National Knowledge Infrastructure (CNKI), Wanfang database, Chinese Science and Technology Journal Database (VIP), and SinoMed (CBM) were searched from inception to 27 May 2026. Randomized controlled trials (RCTs) comparing Huachansu plus chemotherapy with chemotherapy alone were included. Forty-three RCTs involving 3,255 participants and three Huachansu formulations (injection, capsule, and tablet) were eligible. Primary outcomes were disease control rate (DCR) and objective response rate (ORR). Secondary outcomes included overall survival (OS), 3-year survival rate, quality of life, tumor markers, immune indices, angiogenic factors, and reported treatment-related adverse events.ResultsCompared to chemotherapy alone, Huachansu combined with chemotherapy was associated with higher DCR (RR = 1.20, 95% CI: 1.16–1.24) and ORR (RR = 1.42, 95% CI: 1.33–1.51). Formulation-stratified analyses identified a significant subgroup difference for DCR (χ2 = 10.25, P = 0.006), but not for ORR (χ2 = 4.75, P = 0.09). Survival data suggested a potential association with longer overall survival (MD = 2.02 months, 95% CI: 1.42 to 2.63; 2 RCTs) and a higher 3-year survival rate (RR = 1.96, 95% CI: 1.20 to 3.20; 3 RCTs). Tumor-biomarker analyses suggested associations with lower CEA (SMD = −1.59, 95% CI: −2.05 to −1.12; I2 = 91%), CA19-9 (SMD = −1.35, 95% CI: −1.78 to −0.92; I2 = 89%), and CA125 (SMD = −1.16, 95% CI: −1.47 to −0.84; I2 = 64%). Favorable changes were also reported in quality-of-life and selected immune- and angiogenesis-related outcomes. Lower reported incidences of gastrointestinal reactions, oral mucositis, peripheral neuropathy, leukopenia, thrombocytopenia, and hepatic/renal injury were observed.ConclusionHuachansu plus chemotherapy may provide additional clinical benefits in advanced gastrointestinal malignancies, with higher short-term tumor response rates, greater improvements in quality of life, and lower adverse events. Changes in tumor, immune, and angiogenesis-related biomarkers offer exploratory biological insights. Formulation-stratified findings remain inconclusive because of indirect comparisons, and further high-quality, adequately powered RCTs are warranted.Systematic Review RegistrationPROSPERO identifier CRD420261406854.
Related
- Advances in immunotherapy for gastrointestinal malignancies
- Longitudinal Association Between the Change in Serum Procollagen Type III N-Terminal Peptide (PIIINP) and Skeletal Muscle Loss in Patients with Gastrointestinal Cancer Receiving Chemotherapy: A Prospective Cohort Study
- Host Determinants of Adjuvant Chemotherapy Initiation and Survival in Upper Gastrointestinal Adenocarcinoma
- Second Primary Malignancies in Gastrointestinal Cancer Survivors: Epidemiology, Risk Factors, and Future Prediction Models
- Up-Front Immune Checkpoint Inhibitors in Patients with Multiple Synchronous Primary Tumors, Including dMMR/MSI-H Gastrointestinal Malignancies: A Case Series and Review of the Literature.
BibTeX
@article{liu2026huachansu,
title = {{Huachansu combined with chemotherapy for advanced gastrointestinal malignancies: a systematic review and meta-analysis with formulation-stratified analyses}},
author = {Kexin Liu and Xiaoyan Qin and Xinyi Ma and Guanghui Zhu and Jie Li},
journal = {Frontiers in Pharmacology},
year = {2026},
month = nov,
doi = {10.3389/fphar.2026.1920540},
url = {https://www.frontiersin.org/articles/10.3389/fphar.2026.1920540},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Huachansu combined with chemotherapy for advanced gastrointestinal malignancies: a systematic review and meta-analysis with formulation-stratified analyses
AU - Kexin Liu
AU - Xiaoyan Qin
AU - Xinyi Ma
AU - Guanghui Zhu
AU - Jie Li
PY - 2026
DA - 2026/11/02
JO - Frontiers in Pharmacology
DO - 10.3389/fphar.2026.1920540
UR - https://www.frontiersin.org/articles/10.3389/fphar.2026.1920540
AB - AimTo evaluate the clinical effects of Huachansu combined plus chemotherapy compared with chemotherapy alone in advanced gastrointestinal malignancies and to explore potential variation in treatment-effect estimates across Huachansu formulations.MethodsPubMed, Web of Science, the Cochrane Library, China National Knowledge Infrastructure (CNKI), Wanfang database, Chinese Science and Technology Journal Database (VIP), and SinoMed (CBM) were searched from inception to 27 May 2026. Randomized controlled trials (RCTs) comparing Huachansu plus chemotherapy with chemotherapy alone were included. Forty-three RCTs involving 3,255 participants and three Huachansu formulations (injection, capsule, and tablet) were eligible. Primary outcomes were disease control rate (DCR) and objective response rate (ORR). Secondary outcomes included overall survival (OS), 3-year survival rate, quality of life, tumor markers, immune indices, angiogenic factors, and reported treatment-related adverse events.ResultsCompared to chemotherapy alone, Huachansu combined with chemotherapy was associated with higher DCR (RR = 1.20, 95% CI: 1.16–1.24) and ORR (RR = 1.42, 95% CI: 1.33–1.51). Formulation-stratified analyses identified a significant subgroup difference for DCR (χ2 = 10.25, P = 0.006), but not for ORR (χ2 = 4.75, P = 0.09). Survival data suggested a potential association with longer overall survival (MD = 2.02 months, 95% CI: 1.42 to 2.63; 2 RCTs) and a higher 3-year survival rate (RR = 1.96, 95% CI: 1.20 to 3.20; 3 RCTs). Tumor-biomarker analyses suggested associations with lower CEA (SMD = −1.59, 95% CI: −2.05 to −1.12; I2 = 91%), CA19-9 (SMD = −1.35, 95% CI: −1.78 to −0.92; I2 = 89%), and CA125 (SMD = −1.16, 95% CI: −1.47 to −0.84; I2 = 64%). Favorable changes were also reported in quality-of-life and selected immune- and angiogenesis-related outcomes. Lower reported incidences of gastrointestinal reactions, oral mucositis, peripheral neuropathy, leukopenia, thrombocytopenia, and hepatic/renal injury were observed.ConclusionHuachansu plus chemotherapy may provide additional clinical benefits in advanced gastrointestinal malignancies, with higher short-term tumor response rates, greater improvements in quality of life, and lower adverse events. Changes in tumor, immune, and angiogenesis-related biomarkers offer exploratory biological insights. Formulation-stratified findings remain inconclusive because of indirect comparisons, and further high-quality, adequately powered RCTs are warranted.Systematic Review RegistrationPROSPERO identifier CRD420261406854.
SN - 1663-9812
ER -